Cure8 trial brief
This trial tests whether adding nitazoxanide—an antiparasitic with reported antimicrobial and anti-inflammatory effects—can improve symptoms in people with mild-to-moderate ulcerative colitis. If effective, it could point to a novel adjunctive therapy targeting microbes and inflammation.
Adult patients with mild-to-moderate ulcerative colitis, clinicians who treat UC, and researchers interested in microbiome-targeted or repurposed-drug strategies.
This clinicaltrials.gov record describes a randomized, double-blind, placebo-controlled Phase 2/3 trial testing nitazoxanide 500 mg twice daily as an add-on to standard therapy for adults (18–65) with mild-to-moderate ulcerative colitis over 12 weeks. The study plans to enroll 44 participants and lists change in Mayo score at 12 weeks as the primary outcome.
The registry summary notes preclinical rationale (antimicrobial, anti-inflammatory, and barrier-protective effects of nitazoxanide) but emphasizes that clinical evidence to date is limited.
Key eligibility points include stable UC therapy for ≥8 weeks and exclusion of recent antibiotics/probiotics, active intestinal infection, recent biologic initiation or dose change, and pregnancy/lactation. This is a trial record (NOT_YET_RECRUITING) describing planned methods and outcomes; it does not report results or safety findings.
People should not interpret this as evidence that nitazoxanide is effective or safe for UC outside a trial.
This is a registered trial record (Phase 2/3) that is not yet recruiting and does not include results. The registry provides planned design, dose, duration, and outcomes but not efficacy or safety data. Nitazoxanide is not an established UC therapy; enrollment criteria exclude recent antibiotic/probiotic use and recent biologic changes, which may limit generalizability.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This trial tests an oral live biotherapeutic (MH002) aimed at restoring a healthier gut microbiome in people with mild-to-moderate ulcerative colitis. If effective and safe, it would offer a non-immunosuppressive,...
This trial tests whether oral vancomycin can help children with atypical ulcerative colitis or PSC-associated colitis and whether changes in gut bacteria or metabolites explain response. If effective and safe, it could...
This project could introduce a novel, microbiome-targeted oral therapy for Crohn’s disease if the Phase II trial confirms safety and clinical benefit; that matters because many patients need new options when current...
